drugset / Trial / NCT06066606

U-LABA/ICS Effects on Exercise Performance, Vilanterol

NCT06066606

Recruiting 30 enrolled Morten Hostrup, PhD
RandomizedCrossoverQuadruple-blindBasic science

Summary

The purpose of the project is to investigate exercise performance in humans following bronchodilation induced by acute inhalation of beta2-agonist vilanterol + fluticasone furoate

Timeline

Start
2023-10-03
Primary completion
2026-07-15
Completion
2026-12-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Fluticasone Furoate Other / unclassified Inhaled
Subject Vilanterol Other / unclassified 25 ug Inhaled
Subject Vilanterol Other / unclassified 100 ug Inhaled

Indications

No indication recorded.